Hypoglossal Nerve Stimulator for Obstructive Sleep Apnea

Policy MP-004

Origination Date: 04/22/2020

Reviewed/Revised Date: 02/10/2021

Next Review Date: 02/10/2022

Current Effective Date: 04/10/2021

Disclaimer:
1. Policies are subject to change in accordance with State and Federal notice requirements.
2. Policies outline coverage determinations for U of U Health Plans Commercial, and Healthy U (Medicaid) plans. Refer to the “Policy” section for more information.

Description:
Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas, hypopneas, and/or respiratory effort-related arousals caused by repetitive collapse of the upper airway during sleep. The estimated prevalence in North America is approximately 15 to 30 percent in males and 10 to 15 percent in females, when OSA is defined broadly as an apnea-hypopnea index (AHI) greater than five events per hour of sleep. When more stringent definitions are used (e.g., AHI ≥5 events per hour plus symptoms or AHI ≥15 events per hour), the estimated prevalence is approximately 15 percent in males and 5 percent in females.

Patients who meet criteria for a diagnosis of OSA are traditionally classified as having mild, moderate, or severe disease on the basis of the AHI and symptoms. There are multiple options for treatment. Mild disease is defined as having an AHI of 5-14. Moderate disease has an AHI 15-30 and severe disease with an AHI >30. Mild disease is most often treated with positive pressure therapy or oral appliances.

Several therapeutic options are available for the treatment of moderate-to-severe OSA, including continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP), upper airway surgery, oral appliances and upper airway stimulation. The most proven and effective treatment for OSA is continuous positive airway pressure CPAP or BiPAP. However, some patients fail or are intolerant of CPAP or BiPAP therapy. In those instances, many other invasive and noninvasive therapy choices are considered depending on the patient’s characteristics.

Hypoglossal nerve stimulation is one surgical option that may be used for the treatment of moderate-to-severe OSA in adult patients. This therapy includes an implantable device with 3 components: a small implanted pulse generator, a respiratory-sensing lead, and a stimulating lead that are surgically placed on the hypoglossal nerve.
It activates the protrusion muscles of the tongue via the hypoglossal nerve to open the lower pharyngeal airway. It also improves the upper pharyngeal airway by physiological and anatomical coupling of the tongue to the palate, as long as the upper pharynx does not have a concentric collapse pattern. Thus, stimulation has a combined upper and lower pharyngeal airway effect in properly selected patients. The device is activated remotely each night at the time of sleep and deactivated in the morning.

Patients younger than age 22 are not eligible for this therapy nor is anyone with a body mass index >32, enlarged tonsils or with documentation of concentric airway collapse with sleep.

Policy Statement and Criteria

1. Commercial Plans

U of U Health Plans considers Food and Drug Administration (FDA)-approved hypoglossal nerve stimulators medically necessary in adults with moderate-to-severe OSA when ALL the following criteria are met:

   A. Age ≥ 22 years
   B. AHI ≥15 with less than 25% central apneas
   C. A minimum of 3 month trial of CPAP with documentation demonstrating CPAP failure (residual AHI ≥ 20 or inability to tolerate CPAP ≥ 4 hours per night for ≥ 5 nights per week) or inability to tolerate CPAP;
   D. Body mass index (BMI) ≤32 kg/m²
   E. Absence of complete concentric collapse* at the soft palate level as seen on a drug-induced sleep endoscopy (DISE) procedure
   F. No anatomical finding that would compromise the performance of upper airway stimulation (e.g., tonsil size 3 or 4 per tonsillar hypertrophy grading scale).

*Concentric collapse decreases the success of hypoglossal nerve stimulation and is an exclusion criterion from the Food and Drug Administration.

U of U Health Plans considers Food and Drug Administration (FDA)-approved hypoglossal nerve stimulators on young adults or adolescents diagnosed with moderate to severe OSA and Down syndrome medically necessary if ALL the following criteria are met (A-E):

   A. Age 10 to 21 years
   B. AHI >10 and <50 with less than 25% central apneas after prior adenotonsillectomy; AND
   C. Have either tracheotomy or noted to be ineffectively treated with CPAP due to ONE of the following:
      i. Noncompliance,
ii. Discomfort,

iii. Un-desirable side effects,

iv. Persistent symptoms despite compliance use, or

v. Refusal to use the device

D. Body mass index less than or equal to 95th percentile for age

E. Non-concentric retropalatal obstruction on drug-induced sleep endoscopy (DISE).

U of U Health Plans considers hypoglossal nerve stimulation as experimental/investigational for all other indications not listed above.

2. Medicaid Plans

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at:
http://health.utah.gov/medicaid/manuals/directory.php or the Utah Medicaid code Look-Up tool

3. Medicare Plans

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicare policies and coverage, please visit their search website at:

Clinical Rationale

In 2019 (latest review September 2020), Hayes, Inc. reviewed the body of evidence for use of hypoglossal nerve stimulation therapy as a treatment of moderate-to-severe OSA. The review suggests that the therapy is relatively safe and may reduce the severity of OSA and improve patient-reported outcome measures (i.e. excessive daytime sleepiness, function, quality of life) for patients with OSA that have failed or are intolerant to CPAP therapy. However, uncertainty remains due to the low quality of the evidence and the challenges in performing high-quality comparative studies in patients who are refractory to the standard of care for OSA (CPAP). More robust, higher-quality research is necessary to firmly establish the efficacy of this therapy and to identify the patients that are most likely to benefit from the intervention. Nonetheless, it is unlikely that higher-quality evidence will become available unless hypoglossal nerve stimulation becomes indicated for patients with less severe OSA.

Supporting the Hayes findings studies by Strollo et al., (2015), Soose et al., (2016) and Gillespie, et al., (2017) respectively report findings of the STAR trial at 18 months, 24 months and 48 months. These studies assessed AHI and ODI as primary endpoints and identified statistically significant improvement compared to no therapy but again lack comparison to oral appliances or other methods to treat OSA.
The serial studies suggest some level of effectiveness and safety of hypoglossal nerve stimulation as it relates to AHI, ODI and sleep quality measures with some level of durability to these effects. However, these studies also suggest residual clinical disease which may reduce clinical impact of this therapy. In addition, a 2015 systematic review and meta-analysis (Certal et.al.) assessed the evidence regarding the efficacy and safety of hypoglossal nerve stimulation as an alternative therapy in the treatment of OSA. Poor adherence to continuous positive airway pressure treatment in obstructive sleep apnea (OSA) adversely affects the effectiveness of this therapy. Six prospective studies with 200 patients were included in this review. At 12 months, the pooled fixed effects analysis demonstrated statistically significant reductions in AHI, ODI, and ESS mean difference of -17.51 (95% CI: -20.69 to -14.34); -13.73 (95% CI: -16.87 to -10.58), and -4.42 (95% CI: -5.39 to -3.44), respectively. Similar significant reductions were observed at 3 and 6 months. Overall, the AHI was reduced between 50% and 57%, and the ODI was reduced between 48% and 52%. Despite using different hypoglossal nerve stimulators in each subgroup analysis, no significant heterogeneity was found in any of the comparisons, suggesting equivalent efficacy regardless of the system in use. In conclusion, the authors found that hypoglossal nerve stimulation therapy may be considered in selected patients with OSA who fail medical treatment. Although the authors went on to note further studies comparing hypoglossal nerve stimulation with conventional therapies are needed to definitively evaluate outcomes.

A Recent study has emerged on the efficacy and safety of hypoglossal nerve simulator therapy in children with Down Syndrome (DS) that have persistent severe OSA following an adenotonsillectomy (Diercks, et. al., 2018). Participants were 6 children and adolescents (12-18 years) with DS and severe OSA (apnea hypopnea index [AHI] > 10 events/h) despite prior adenotonsillectomy and were often unable to tolerate CPAP. The authors concluded that hypoglossal nerve stimulation was well tolerated and effective in this study population, representing a potential therapeutic option for patients with DS and refractory OSA after adenotonsillectomy as they are frequently unable to tolerate CPAP devices. According to Costantino et al., as of 2019 there were no available RCTs that compared hypoglossal nerve stimulation (HGNS) to CPAP or other surgical therapies. The majority of the available HGNS studies are prospective, retrospective or case series. The authors concluded that the limited available evidence shows that HGNS has obtained a high surgical success rate with reasonable long-term complication rate related to the device implanted. Furthermore, the procedure represents an effective and safe surgical treatment for moderate-severe OSA in selected adult patients > 22 years of age who had difficulty accepting or adhering to CPAP.

A safety study of Hypoglossal nerve stimulation (HNS) detailed 20 children with Down Syndrome and severe OSA (AHI of 10 or greater) that were treated at 3 tertiary care centers (Caloway et al., 2020). Included were non-obese (BMI < 95%) children and adolescents aged 10-21 years who were refractory to tonsillectomy and either unable to tolerate CPAP or dependent on a tracheostomy. Patients were included whose AHI was between 10 and 50 on baseline PSG; the median baseline AHI was 24.15 (interquartile range [IQR] of 19.88 to 35.10). All of the patients tolerated the stimulation, and at 2 months after implantation the median AHI was 3.56 (IQR 2.61 to 4.40). Success, defined as an AHI of 5 or less (mild) with HNS, was achieved in 14 of 20 patients (70%). The median percent reduction in AHI was 85% with a median usage of 9.21 h (IQR: 8.29 to 9.50) per night. The OSA-18 score improved by 1.15 (IQR: 0.02 to 1.97), indicating a moderate but clinically significant change. There were 2 adverse events related to extrusion or connectivity of the stimulation or sensation leads, which were both corrected with wound exploration surgery. The authors concluded that overall, these data suggest that pediatric HGN stimulation appears to be a safe and effective therapy for children with DS and refractory severe OSA. However, a study in a larger population of children with Down Syndrome is ongoing.
In 2020, a multicenter prospective observational study (Thaler et al.) detailed the outcomes of the ADHERE Registry. This international study followed outcomes of upper airway stimulation (UAS) therapy in patients who have failed continuous positive airway pressure therapy for OSA. The registry enrolled adult participants who meet the approved indications of UAS including AHI between 15 to 65 events per hour inclusive, who are intolerant to CPAP, and who are free of complete concentric collapse during sedated endoscopy. Average age was 60 years, BMI of 29.3 kg/m2 and 74% male. A total of 97% of participants reported history of positive airway pressure use for treatment of OSA: 20% with oral appliances, 22% with nasal procedures, 29% with palatal procedures, and 5% with tongue-base procedures. Demographic and sleep study data collection occurred at baseline, implantation visit, post-titration (6 months), and final visit (12 months). Patient and physician reported outcomes were collected. Predictors of therapy response were defined as ≥50% decrease in AHI and AHI ≤20 at the 12-month visit. The registry has enrolled 1,017 patients from October 2016 through February 2019. To date, 640 patients have completed their six-month follow-up and 382 have completed the 12-month follow-up. After 12 months, median AHI was reduced from 32.8 to 9.5. Epworth Sleepiness Scale was similarly improved from 11.0 to 7.0. Therapy usage was 5.6 ± 2.1 hours per night after 12 months. Only female sex and lower baseline body mass index remained as significant predictors of therapy response. Stimulation related discomfort was reported by 12% of participants at six months and 8% of participants at 12 months post-implantation. Surgical intervention was required for device revision in three cases: in one participant due to stimulation electrode dislodgement within six months and in another two individuals with stimulation electrode repositioning within 12 months. A reported limitation of this study is that both home and in-laboratory studies were used in the analysis, with attendant lack of uniformity of AHI recording. Home sleep studies may underestimate AHI. In conclusion, the authors found that UAS therapy continues to show significant improvement in subjective and objective OSA outcomes. Also, this multi-international study shows that the therapy effect is durable and adherence is high.

As of 2017, the National Institute for Health and Care Excellence (NICE) noted hypoglossal nerve stimulation as a treatment choice for moderate to severe OSA. However, they state that it should only be used with special arrangements for clinical governance, consent and audit or research, as evidence on its efficacy and safety is limited in quantity and quality.

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Foundation issued a position statement in 2019 stating that it considers upper airway stimulation via the hypoglossal nerve to be an effective second-line treatment of moderate-to-severe OSA in adult patients who are intolerant of or unable to achieve benefit with positive airway pressure. However, not all adult patients are candidates for this therapy; appropriate polysomnographic, age, body mass index, and objective upper airway evaluation measures are required for proper patient selection. The AAO-HNS Foundation does note that its position statements are based on an informal process of expert or committee consensus that draws upon the best available evidence, but is not a formal technology assessment.

The April 14, 2020 FDA PMA supplemental document for Inspire UAS (P130008 S039) has an approval order statement for the Inspire Upper Airway Stimulation. The device is used to treat a subset of patients with moderate to severe OSA (AHI of greater than or equal to 15 and less than or equal to 65). Inspire UAS is used in adult patients 22 years of age and older who have been confirmed to fail or cannot tolerate positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BPAP] machines) and who do not have a complete concentric collapse at the soft palate level. PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as:

A. Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night); or
B. Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it). Inspire UAS is also indicated for use in patients between the ages of 18 and 21 with moderate to severe OSA (15<=AHI<=65) who:

- Do not have complete concentric collapse at the soft palate level;
- Are contraindicated for or not effectively treated by adenotonsillectomy;
- Have been confirmed to fail, or cannot tolerate PAP therapy despite attempts to improve compliance; and
- Have followed standard of care in considering all other alternative/adjunct therapies.

The FDA warnings and precautions section of the Labeling documents from 2014 state that BMI greater than 32 was not studied as part of the pivotal trial. Therefore, it may be associated with decreased likelihood of response to treatment. Use of Inspire UAS in higher BMI patients is not recommended due to unknown effectiveness and safety.

**Applicable Coding**

**CPT Codes**

*Covered if coverage criteria met*

- **0466T** Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator (List separately in addition to code for primary procedure)
- **0467T** Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator
- **0468T** Removal of chest wall respiratory sensor electrode or electrode array
- **64568** Incision for implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator

**HCPCS Codes**

No applicable codes

**References:**


Disclaimer:
This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s individual benefit plan that is in effect at the time services are rendered. The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans” and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association